Linda Trinh, NP
Nurse Practitioner · Irvine, CANPI 1124333828
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $646,545 of the $883,785 with a category attached, or 73.2%. 45 manufacturers reported payments, led by Johnson & Johnson at 37.1% of the total. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,890 payments — averaging $467.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$328K
- Neurocrine Biosciences, Inc.$231K
- Alkermes, Inc.$175K
- Teva Pharmaceuticals USA, Inc.$66K
- AbbVie$38K
- E.r. Squibb & Sons, L.L.C.$20K
- plus $24K from 39 others
Across 1 payment — averaging $15,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vanda Pharmaceuticals Inc.$15K
What the payments were for
- Consulting fees$77,6009%
- Speaking & faculty fees$646,54573%
- Travel & lodging$113,55313%
- Food & beverage$45,9795%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$408,111
- ARISTADA$276,427
- INGREZZA$227,571
- INVEGA SUSTENNA$186,533
- INVEGA TRINZA$184,468
- SPRAVATO$136,755
- ARISTADA INITIO$62,564
- VRAYLAR$35,182
- UZEDY$25,000
- Austedo XR$23,034
- AUSTEDO$13,787
- COBENFY$10,823
- Zurzuvae$2,430
- REXULTI$366
- CAPLYTA$259
- VALTOCO$125
- Edwards SAPIEN 3 Transcatheter Heart Valve$125
- NURTEC ODT$125
- Dayvigo$125
- JORNAY PM$125
How this compares
$883,785 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 54 | $598,492 |
| Austedo XrDeutetrabenazine | 27 | $126,275 |
| AristadaAripiprazole Lauroxil | 23 | $70,206 |
| Invega SustennaPaliperidone Palmitate | 17 | $60,061 |
| CaplytaLumateperone Tosylate | 16 | $26,717 |
| TrintellixVortioxetine Hydrobromide | 22 | $21,667 |
| Lurasidone Hcl | 28 | $11,567 |
| Aripiprazole | 73 | $5,551 |
| Quetiapine Fumarate | 114 | $2,886 |
| Trazodone Hcl | 120 | $2,130 |
| Clozapine | 25 | $1,950 |
| Divalproex Sodium ErDivalproex Sodium | 44 | $1,376 |
| Bupropion XlBupropion Hcl | 70 | $1,230 |
| Fluoxetine Hcl | 60 | $1,096 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 50 | $1,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $231,475 | $598,49254 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $66,287 | $126,27527 claims |
| Alkermes, Inc.Aristada | $175,093 | $70,20623 claims |
| Johnson & JohnsonInvega Sustenna | $328,325 | $60,06117 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,975 | $26,71716 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $143 | $21,66722 claims |
| Almatica Pharma LLCSertraline Hcl | $51 | $96090 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Irvine
- Thu Michelle TranIrvine$33K
- Rhonda HewittStanford$917K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.